DGX · Quest Diagnostics Incorporated

This debt financing represents a strategic refinancing move by Quest Diagnostics to replace imminent near-term debt with longer-dated, fixed-rate obligations. The $500 million 5.000% senior notes due 2036 directly offset the Company’s $500 million 3.45% Senior Notes maturing June 1, 2026 — effectively rolling over an entire tranche of debt while extending average maturity by ten years. Though the new coupon is 155 basis points higher than the retiring notes, the trade-off reflects current market rates and reduces near-term refinancing risk. The transaction was executed under an automatic shelf registration statement (File No. 333-288188), confirming the Company’s well-known seasoned issuer status and enabling efficient capital markets access. Closing is scheduled for May 6, 2026, subject to customary conditions, meaning proceeds will not be available until after the existing notes’ maturity date — implying the Company will likely use short-term liquidity or bridge financing to meet the June 1 obligation. The involvement of three major underwriters — Goldman Sachs, J.P. Morgan, and Mizuho — signals strong investor demand and execution capability. Importantly, the filing explicitly limits use of proceeds to general corporate purposes, with no disclosure of acquisitions, share repurchases, or dividend enhancements — indicating this is a balance sheet management action rather than growth or return-of-capital initiative. Given the size relative to total debt and the direct impact on upcoming maturity coverage, this event carries high materiality for credit investors and equity holders assessing financial flexibility and interest expense trajectory.